BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20809393)

  • 1. Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins.
    Rwigema JC; Heron DE; Parikh SD; Zeh HJ; Moser JA; Bahary N; Ashby K; Burton SA
    J Gastrointest Cancer; 2012 Mar; 43(1):70-6. PubMed ID: 20809393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
    Chang DT; Schellenberg D; Shen J; Kim J; Goodman KA; Fisher GA; Ford JM; Desser T; Quon A; Koong AC
    Cancer; 2009 Feb; 115(3):665-72. PubMed ID: 19117351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
    Tozzi A; Comito T; Alongi F; Navarria P; Iftode C; Mancosu P; Reggiori G; Clerici E; Rimassa L; Zerbi A; Fogliata A; Cozzi L; Tomatis S; Scorsetti M
    Radiat Oncol; 2013 Jun; 8():148. PubMed ID: 23799996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
    Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
    Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
    PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
    Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
    Schellenberg D; Kim J; Christman-Skieller C; Chun CL; Columbo LA; Ford JM; Fisher GA; Kunz PL; Van Dam J; Quon A; Desser TS; Norton J; Hsu A; Maxim PG; Xing L; Goodman KA; Chang DT; Koong AC
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):181-8. PubMed ID: 21549517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study.
    Comito T; Cozzi L; Zerbi A; Franzese C; Clerici E; Tozzi A; Iftode C; Navarria P; D'Agostino G; Fogliata A; Mancosu P; Tomatis S; Carnaghi C; Personeni N; Santoro A; Scorsetti M
    Eur J Surg Oncol; 2017 Apr; 43(4):735-742. PubMed ID: 28131670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients.
    Kim CH; Ling DC; Wegner RE; Flickinger JC; Heron DE; Zeh H; Moser AJ; Burton SA
    Radiat Oncol; 2013 Oct; 8():240. PubMed ID: 24131503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.
    Gkika E; Adebahr S; Kirste S; Schimek-Jasch T; Wiehle R; Claus R; Wittel U; Nestle U; Baltas D; Grosu AL; Brunner TB
    Strahlenther Onkol; 2017 Jun; 193(6):433-443. PubMed ID: 28138949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.
    Poiset SJ; Shah S; Cappelli L; Anné P; Mooney KE; Werner-Wasik M; Laufer TS; Posey JA; Lin D; Basu Mallick A; Lavu H; Bashir B; Yeo CJ; Mueller AC
    Radiat Oncol; 2024 May; 19(1):65. PubMed ID: 38812040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.
    Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD
    J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
    Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
    Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective.
    Ryan JF; Groot VP; Rosati LM; Hacker-Prietz A; Narang AK; McNutt TR; Jackson JF; Le DT; Jaffee EM; Zheng L; Laheru DA; He J; Pawlik TM; Weiss MJ; Wolfgang CL; Herman JM
    Ann Surg Oncol; 2018 Jan; 25(1):280-289. PubMed ID: 29063299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
    Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.
    Lischalk JW; Burke A; Chew J; Elledge C; Gurka M; Marshall J; Pishvaian M; Collins S; Unger K
    J Gastrointest Cancer; 2018 Jun; 49(2):116-123. PubMed ID: 28044263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma.
    Simoni N; Micera R; Paiella S; Guariglia S; Zivelonghi E; Malleo G; Rossi G; Addari L; Giuliani T; Pollini T; Cavedon C; Salvia R; Milella M; Bassi C; Mazzarotto R
    Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e31-e38. PubMed ID: 32682686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer: A single center experience.
    Jumeau R; Delouya G; Roberge D; Donath D; Béliveau-Nadeau D; Campeau MP
    Dig Liver Dis; 2018 Apr; 50(4):396-400. PubMed ID: 29326012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
    Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.